Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

Could the same medication that causes people to lose weight hold the key to reducing drinking? In a new paper at the European ...

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.